A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Dioxoles
  • Isoquinolines
  • Neoplasms

abstract

  • The maximum tolerated dose of ET-743 that can be administered repetitively is 325 microg/m(2)/day daily x 5 every 3 weeks, which is recommended for disease-directed clinical trials. The acceptable toxicity profile of ET-743 on the divided-dose schedule evaluated in this trial, as well as the generally superior antitumor activity associated with divided-dose schedules in preclinical studies, provides a rationale for further evaluation of ET-743 on this administration schedule.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11801542

Additional Document Info

start page

  • 75

end page

  • 85

volume

  • 8

number

  • 1